{"schema_version":"secwatch.filing_event.v1","accession":"0001437402-26-000021","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.288076+00:00","generated_at":"2026-05-15T00:39:10.500122+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ardelyx Q1 revenue $93.4M (+38% YoY); IBSRELA revenue $70.1M (+58% YoY)","bullets":["Net loss $37.6M ($0.15/sh) vs $41.1M ($0.17/sh) Q1 2025; share-based comp $14.2M.","Cash & investments $238.1M as of Mar 31, 2026; reiterated FY 2026 IBSRELA guidance $410-430M.","IBSRELA Phase 3 CIC trial (ACCEL) enrolling; topline data expected H2 2027.","Appointed Rajani Dinavahi, M.D. as CMO and Felecia Ettenberg, Esq. as CLO in April.","Refinanced debt with SLR Investment Corp for better terms; Morgan Stanley advised."],"urls":{"canonical":"https://secwatch.observer/filing/0001437402-26-000021","json":"https://secwatch.observer/filing/0001437402-26-000021.json","markdown":"https://secwatch.observer/filing/0001437402-26-000021.md","text":"https://secwatch.observer/filing/0001437402-26-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000143740226000021/0001437402-26-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000143740226000021/ardx-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:39:10.500122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d94871d030b57cbfab389c627d41ce67a6a2e165","claim":"ARDELYX, INC. reported quarter ended March 31, 2026 results: revenue Total product revenue for the quarter ended March 31, 2026 was $93.4 million, net income Net loss for the quarter ended March 31, 2026 was $37.6 million, EPS $(0.15) per share.","evidence_excerpt":"Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1437402/000143740226000021/0001437402-26-000021-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Revenue","value":"Total product revenue for the quarter ended March 31, 2026 was $93.4 million"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2026 was $37.6 million"},{"label":"EPS","value":"$(0.15) per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}